Daré Bioscience, Inc.
DARE
$0.72
$0.011.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.37M | 1.16M | 1.03M | -57.10K | -17.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.37M | 1.16M | 1.03M | -57.10K | -17.70K |
| Cost of Revenue | -1.97M | -1.10M | 295.90K | -6.08M | -4.57M |
| Gross Profit | 3.33M | 2.26M | 734.40K | 6.02M | 4.55M |
| SG&A Expenses | 8.92M | 8.70M | 8.76M | 9.18M | 8.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.48M | 13.13M | 14.58M | 17.41M | 18.46M |
| Operating Income | -11.11M | -11.97M | -13.55M | -17.47M | -18.48M |
| Income Before Tax | -10.99M | -12.02M | -13.40M | -17.46M | -18.60M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.99 | -12.02 | -13.40 | -17.46 | -18.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.99M | -12.02M | -13.40M | -17.46M | -18.60M |
| EBIT | -11.11M | -11.97M | -13.55M | -17.47M | -18.48M |
| EBITDA | -8.97M | -9.95M | -11.91M | -16.35M | -17.83M |
| EPS Basic | -0.79 | -1.04 | -1.33 | -1.92 | -2.19 |
| Normalized Basic EPS | -0.49 | -0.65 | -0.83 | -1.20 | -1.37 |
| EPS Diluted | -0.89 | -1.14 | -1.43 | -1.92 | -2.19 |
| Normalized Diluted EPS | -0.49 | -0.65 | -0.83 | -1.20 | -1.37 |
| Average Basic Shares Outstanding | 56.45M | 50.43M | 44.67M | 38.40M | 34.18M |
| Average Diluted Shares Outstanding | 56.45M | 50.43M | 44.67M | 38.40M | 34.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |